CN105147693A - 一种小分子化合物在制备抗肺癌药物中的应用 - Google Patents
一种小分子化合物在制备抗肺癌药物中的应用 Download PDFInfo
- Publication number
- CN105147693A CN105147693A CN201510608172.1A CN201510608172A CN105147693A CN 105147693 A CN105147693 A CN 105147693A CN 201510608172 A CN201510608172 A CN 201510608172A CN 105147693 A CN105147693 A CN 105147693A
- Authority
- CN
- China
- Prior art keywords
- cell
- small
- micromolecular compound
- molecule compound
- lung
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010058467 Lung neoplasm malignant Diseases 0.000 title claims abstract description 17
- 201000005202 lung cancer Diseases 0.000 title claims abstract description 9
- 208000020816 lung neoplasm Diseases 0.000 title claims abstract description 9
- -1 small-molecule compound Chemical class 0.000 title abstract description 6
- 239000003560 cancer drug Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 claims description 41
- 239000003814 drug Substances 0.000 claims description 8
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 claims description 3
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Substances C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 abstract description 54
- 230000006907 apoptotic process Effects 0.000 abstract description 20
- 230000000694 effects Effects 0.000 abstract description 19
- 238000002474 experimental method Methods 0.000 abstract description 9
- 102000047934 Caspase-3/7 Human genes 0.000 abstract description 8
- 108700037887 Caspase-3/7 Proteins 0.000 abstract description 8
- 210000001700 mitochondrial membrane Anatomy 0.000 abstract description 8
- 108090000397 Caspase 3 Proteins 0.000 abstract description 3
- 102100029855 Caspase-3 Human genes 0.000 abstract description 3
- 230000001419 dependent effect Effects 0.000 abstract description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 abstract description 3
- 230000001939 inductive effect Effects 0.000 abstract description 2
- 230000006667 mitochondrial pathway Effects 0.000 abstract description 2
- 230000003285 pharmacodynamic effect Effects 0.000 abstract description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 abstract description 2
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 25
- 239000012531 culture fluid Substances 0.000 description 13
- 238000000034 method Methods 0.000 description 12
- 239000006285 cell suspension Substances 0.000 description 11
- 230000008569 process Effects 0.000 description 11
- 230000001640 apoptogenic effect Effects 0.000 description 10
- 238000004113 cell culture Methods 0.000 description 8
- 230000006698 induction Effects 0.000 description 8
- 238000000684 flow cytometry Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 239000012980 RPMI-1640 medium Substances 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 238000004043 dyeing Methods 0.000 description 5
- 239000013589 supplement Substances 0.000 description 5
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 210000003470 mitochondria Anatomy 0.000 description 4
- 102000011727 Caspases Human genes 0.000 description 3
- 108010076667 Caspases Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000003731 Caspase Glo 3/7 Assay Methods 0.000 description 2
- 102000004039 Caspase-9 Human genes 0.000 description 2
- 108090000566 Caspase-9 Proteins 0.000 description 2
- 102000005927 Cysteine Proteases Human genes 0.000 description 2
- 108010005843 Cysteine Proteases Proteins 0.000 description 2
- 102000010911 Enzyme Precursors Human genes 0.000 description 2
- 108010062466 Enzyme Precursors Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000002424 anti-apoptotic effect Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 239000012148 binding buffer Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 206010010144 Completed suicide Diseases 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000002259 TNF-Related Apoptosis-Inducing Ligand Receptors Human genes 0.000 description 1
- 108091007178 TNFRSF10A Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- GLLRIXZGBQOFLM-UHFFFAOYSA-N Xanthorin Natural products C1=C(C)C=C2C(=O)C3=C(O)C(OC)=CC(O)=C3C(=O)C2=C1O GLLRIXZGBQOFLM-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 230000005775 apoptotic pathway Effects 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 238000010523 cascade reaction Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000019628 coolness Nutrition 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 230000025915 regulation of apoptotic process Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种小分子化合物在制备抗肺癌药物中的应用;本发明通过药理药效学实验证明,该小分子化合物对人非小细胞肺癌细胞株A549细胞具有显著的抑制增殖、诱导凋亡等作用;实验结果表明该小分子化合物可以显著降低线粒体膜电位,并且有明显的caspase3/7活性。说明该小分子化合物是通过caspase-3依赖型线粒体途径来诱导A549细胞的凋亡。
Description
技术领域
本发明涉及生物医药领域,具体涉及一种新型小分子化合物在制备抗肺癌药物中的应用。
背景技术
恶性肿瘤已经成为严重威胁人类健康与生活质量的主要原因之一。肺癌是最常见的恶性肿瘤之一,在全世界范围内肺癌的发病率和死亡率均呈上升趋势,尤其是在中国等发展中国家。在我国,随着工业化速度加快、环境污染加重、人口老龄化加剧,肺癌的患病率以及致死率日益加重。因此,寻找治疗肺癌的有效方法已经成为目前最为迫切的任务之一。
肺癌的治疗方法包括手术治疗、放射治疗、药物治疗等。目前肺癌的治疗已从最初的手术治疗的单一手段发展到今天的手术切除、放射治疗和内科治疗为一体的综合治疗模式。另外,80%的肺癌患者在发现时已属于晚期,大多患者仍以药物治疗为主。鉴于传统药物严重的毒副作用以及耐药性等问题,研究开发新的高效、肿瘤特异性以及毒副作用小的药物成为治疗肺癌的主攻方向之一。
近年来,随着分子生物学对生命和肿瘤研究的不断深入,针对特定生理过程和靶点的分子靶向药物以其独特的疗效和远大的前景在肺癌治疗中引起了广泛关注。化学合成的有机小分子是一种分子量小、容易进入细胞、可以与其中的蛋白质分子结合并影响蛋白活性的一种化合物。在抗肿瘤药物的筛选中,活性化合物可被视为一种药物先导化合物,为后续进行的结构修饰、药理学研究、药代动力学分析等奠定基础。除此之外,还可以进一步寻找活性化合物的作用靶点及作用机制,从而为药物研发提供新的靶点。
细胞凋亡是程序性细胞死亡的一种形式之一,是细胞一种生理性、主动性的细胞“自杀行为”,是一个受到一系列相关基因严格调控的细胞死亡过程。凋亡不会引起后续的炎症等不良反应,因此已经成为研究抗癌药物的主要方式之一。不同的凋亡信号在细胞中引发不同的凋亡信号转导通路。根据凋亡信号的来源可以将细胞凋亡信号转导通路分成两条:外源性通路(死亡受体通路)和内源性通路(线粒体通路)。
线粒体是细胞凋亡调控的活动中心。当受到细胞凋亡信号刺激。线粒体释放细胞色素C至细胞浆中。细胞色素C与细胞内存在的一种凋亡细胞蛋白酶激活因子(Apoptosis
Protease Activating Factor-1,Apaf-1)结合,在dATP存在的条件下,通过半胱氨酸蛋白酶募集域的作用,Apaf-1和Caspase-9酶原结合。使Caspase-9酶原活化,然后激活下游的效应半胱氨酸蛋白酶如Caspase-3、6,7等成员,从而启动细胞凋亡。
Caspase全称为含半胱氨酸的天冬氨酸蛋白水解酶(cysteinyl aspartate specific proteinase)。该家族是直接导致凋亡细胞解体的蛋白酶系统,在细胞凋亡机制网络中居中心地位,是一组在细胞凋亡过程中起着关键作用的酶。Caspase家族在诱导细胞凋亡的分子机制中起着关键作用,是多条凋亡通路的汇聚点,是执行凋亡的最终途径。Caspass-3是迄今为止研究比较透彻的一个,它是主要的效应者分子。其中Caspase-3被认为是凋亡的关键蛋白酶,一旦被激活,即发生下游的级联反应,使凋亡不可避免,因而Caspase-3被称为“死亡蛋白酶”。
发明内容
本发明的目的在于提供了一种小分子化合物在制备抗肺癌药物中的应用;本发明通过药理药效学实验证明,该小分子化合物对人非小细胞肺癌细胞株A549细胞具有显著的抑制增殖、诱导凋亡等作用。
本发明所述的小分子化合物 如下:
8-[(E)-2-[(4-bromophenyl)methylidene]hydrazin-1-yl]-3-methyl-7-(2-phenoxyethyl)-2,3,6,7-tetrahydro-1H-purine-2,6-dione(购自Life Chemicals Small Molecules Collection公司);
化学结构式如下:
;
中文名称为:8-[(E)-2-[(4-溴苯基)亚甲基]联氨-1-基]-3-甲基-7-(2-苯氧乙基)-2,3,6,7-四氢-1H-嘌呤-2,6-二酮。
本发明所述小分子化合物在制备抗肺癌药物中的应用;其中肺癌细胞为非小细胞肺癌细胞株A549细胞。
MTT法检测该小分子化合物能有效抑制A549细胞的生长,抑制细胞存活率IC50浓度为4.945 ±0.402 μM。
Hoechst
33342染色结果显示,该小分子化合物可以使A549细胞的细胞核发生明显的核皱缩现象。
流式细胞术结果显示,该小分子化合物对A549细胞具有明显的诱导凋亡作用。
用JC-1染色检测线粒体膜电位的结果显示,该小分子化合物可以使A549细胞的线粒体膜电位显著降低,即通过线粒体途径诱导A549细胞的凋亡。
Caspase水平分析结果显示,该小分子化合物可以显著增强A549细胞内Caspase 3/7的活性,即该小分子化合物通过caspase 3/7依赖型途径诱导A549细胞的凋亡。
附图说明
图1为MTT法检测该小分子化合物对A549细胞的生长抑制作用结果;
图2为流式细胞技术检测DMSO对A549细胞凋亡的影响结果;
图3为流式细胞技术检测2.5 μM的该小分子化合物 对A549细胞凋亡的影响结果;
图4为流式细胞技术检测5 μM的该小分子化合物对A549细胞凋亡的影响结果;
图5为流式细胞技术检测10 μM的该小分子化合物对A549细胞凋亡的影响结果;
图6为线粒体膜电位检测试剂盒(JC-1)检测该小分子化合物诱导A549细胞线粒体膜电位的变化情况(**P<0.01)结果;
图7为Caspase-Glo® 3/7 Assay(Promega)检测该小分子化合物处理的A549细胞中Caspase 3/7活性的变化情况结果(**P<0.01)。
具体实施方式
下面通过实施例对本发明作进一步详细说明,但本发明的保护范围不局限于所述内容,实施例中方法如无特殊说明均采用常规方法,使用试如无特殊说明,均为常规市售试剂或采用常规方法配置的试剂。
实施例 1:通过MTT法检测该小分子化合物对A549细胞存活率的影响,实验步骤如下:
(1)取胰酶消化对数期细胞,用RPMI-1640培养液调整细胞悬液浓度为5×104cell/ml,加入96孔细胞培养板中,每孔加入100 μl细胞悬液,然后放入37℃的细胞培养箱,培养箱的CO2浓度为5%,培养24h;
(2)该小分子化合物的原溶液浓度为10 mM,用DMSO进行浓度梯度稀释,浓度梯度为10 μM、5 μM、2.5 μM、1.25 μM,每个梯度每孔加入1μl,设三个复孔,补充100 μl RPMI-1640培养液;同时设置加入1 μl 0.5% DMSO为对照组,继续放入培养箱中培养72h;
(3)每孔加入MTT溶液20μl,37℃培养4h后,去上清,用100μl DMSO溶解剩余的甲瓒结晶,酶标仪检测490nm处的吸光值,计算该小分子化合物对A549细胞生长的抑制率及其IC50值;细胞抑制率 =(1-加药组平均OD 值/ 对照组平均OD 值)×100%。
结果见图1,该小分子化合物对A549细胞具有显著的抑制生长作用且呈明显的浓度依赖效应。
实施例2:Hoechst 33342染色观察小分子化合物处理过的A549细胞的核皱缩现象
本实验通过Hoechst 33342染色(碧云天)检测小分子化合物处理的A549细胞的核皱缩现象,实验步骤如下:
(1)取胰酶消化对数期细胞,用RPMI-1640培养液调整细胞悬液浓度为1×105cell/ml,加入24孔细胞培养板中,每孔加入0.5ml细胞悬液,然后放入37℃的细胞培养箱,培养箱的CO2浓度为5%,培养24h;
(2)分别加入5μl 5μM、2.5 μM的该小分子化合物,补充0.5ml RPMI-1640培养液,同时设置加入5μl 0.5%DMSO为对照组,继续放入培养箱中培养24h;
(3)吸除培养基,多聚甲醛(工作浓度10μg/ml)固定10min,吸除多聚甲醛,PBS清洗两次,加入100μl 100μg/ml的Hoechst 33342染色液,用1 ml
PBS稀释至工作浓度10μg/ml,染色15 min,吸除染色液,用PBS清洗三次,每次3-5 min,置于荧光显微镜下观察细胞的核皱缩现象;
结果显示,DMSO处理的A549细胞的细胞核呈现正常的蓝色且细胞核完整为椭圆形;2.5 μM 该小分子化合物处理过的A549细胞的细胞核发出亮蓝色荧光且细胞核由于发生显著地皱缩现象而呈现为月牙形;5 μM 该小分子化合物处理过的A549细胞的细胞核发出亮蓝色荧光且细胞核呈现碎块状;由此我们可以初步判断细胞发生了凋亡。
实施例3:通过流式细胞技术检测该小分子化合物诱导A549细胞的凋亡情况
本实验通过Annexin
V-FITC流式检测试剂盒(北京四正柏生物科技有限公司)检测小分子化合物诱导A549细胞凋亡的情况,实验步骤如下:
(1)取胰酶消化对数期细胞,用RPMI-1640培养液调整细胞悬液浓度为5×105cell/ml,加入6孔细胞培养板中,每孔加入1ml细胞悬液,然后放入37℃的细胞培养箱,培养箱的CO2浓度为5%,培养24h;
(2)分别加入10μl 10μM、5 μM、2.5μM的该小分子化合物,补充1ml RPMI-1640培养液。同时设置加入10μl 0.5%DMSO为对照组。继续放入培养箱中培养24h;
(3)用胰酶消化细胞,收集细胞悬液,按照试剂盒说明书稀释结合缓冲液,用4℃预冷的PBS洗涤细胞两次,用500μl结合缓冲液重悬细胞,加入5μl Annexin V-FITC和10μl 20μg/ml的碘化丙啶溶液,混匀后于室温避光孵育15min,以DMSO组为阴性对照用流式细胞仪检测细胞凋亡。
结果见图2- 5,我们可以得出结论:该小分子化合物可以诱导A549细胞发生明显的凋亡现象且呈浓度依赖效应。
实施例4:通过线粒体膜电位检测试剂盒(JC-1)(碧云天)检测该小分子化合物诱导A549细胞的线粒体膜电位的变化情况,实验步骤如下:
(1)取胰酶消化对数期细胞,用RPMI-1640培养液调整细胞悬液浓度为5×104cell/ml,加入96孔黑色透明底细胞培养板中,每孔加入100 μl细胞悬液,然后放入37℃的细胞培养箱,培养箱的CO2浓度为5%,培养24h;
(2)用10 μM、5 μM、2.5 μM 的小分子化合物处理A549细胞,每个梯度每孔加入1 μl,设三个复孔,补充100 μl RPMI-1640培养液。同时设置加入1 μl 0.5%DMSO为对照组。继续放入培养箱中培养24h;
(3)吸除旧培养基,PBS洗涤两次。加入100 μl细胞培养液与100 μl JC-1染色工作液(完全按照碧云天提供的说明书进行配制),充分混匀。细胞培养箱中37℃孵育20分钟;
(4)在孵育期间,按照每1ml
JC-1染色缓冲液(5×)加入4ml蒸馏水的比例,配制适量的JC-1染色缓冲液(1×),并放置于冰浴;
(5)37℃孵育结束后, 吸除上清,用JC-1染色缓冲液(1×)洗涤2次;
(6)加入200 μl细胞培养液,培养液中可以含有血清和酚红;
(7)通过酶标仪进行荧光检测,检测JC-1单体时激发光设置为490nm,发射光设置为530nm;检测JC-1聚合物时,激发光设置为525nm,发射光设置为590nm。
结果见图6,该小分子化合物可以使A549细胞的线粒体膜电位显著降低,即通过线粒体途径诱导A549细胞的凋亡。
实施例5:通过Caspase-Glo® 3/7
Assay(Promega)检测该小分子化合物处理的A549细胞中Caspase 3/7活性的变化,实验步骤如下:
(1)取胰酶消化对数期细胞,用RPMI-1640培养液调整细胞悬液浓度为5×104cell/ml,加入96孔白底细胞培养板中,每孔加入100 μl细胞悬液,然后放入37℃的细胞培养箱,培养箱的CO2浓度为5%,培养24h;
(2)分别用1μl 10 μM、5 μM、2.5 μM的该小分子化合物处理A549细胞24h,设三个复孔,补充100 μl RPMI-1640培养液。同时设置加入1 μl 0.5%DMSO为对照组。继续放入培养箱中培养24h;
(3)吸除培养基,加入100 μl培养基与100 μl 分析试剂(完全按照说明书进行配制),振荡,于室温避光培养1 h,用酶标仪检测Caspase 3/7的活性;
结果见图7,该小分子化合物可以显著增强A549细胞内Caspase 3/7的活性,即该小分子化合物通过caspase 3/7依赖型途径诱导A549细胞的凋亡。
Claims (1)
1.结构式为式I所示的小分子化合物在制备抗肺癌药物中的应用,
式Ⅰ:
8-[(E)-2-[(4-溴苯基)亚甲基]联氨-1-基]-3-甲基-7-(2-苯氧乙基)-2,3,6,7-四氢-1H-嘌呤-2,6-二酮。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510608172.1A CN105147693B (zh) | 2015-09-23 | 2015-09-23 | 一种小分子化合物在制备抗肺癌药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510608172.1A CN105147693B (zh) | 2015-09-23 | 2015-09-23 | 一种小分子化合物在制备抗肺癌药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105147693A true CN105147693A (zh) | 2015-12-16 |
CN105147693B CN105147693B (zh) | 2018-01-12 |
Family
ID=54788976
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510608172.1A Active CN105147693B (zh) | 2015-09-23 | 2015-09-23 | 一种小分子化合物在制备抗肺癌药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105147693B (zh) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101928288A (zh) * | 2000-11-02 | 2010-12-29 | 斯隆-凯特林癌症研究所 | 结合hsp90的小分子组合物 |
-
2015
- 2015-09-23 CN CN201510608172.1A patent/CN105147693B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101928288A (zh) * | 2000-11-02 | 2010-12-29 | 斯隆-凯特林癌症研究所 | 结合hsp90的小分子组合物 |
Non-Patent Citations (2)
Title |
---|
MAYA GEORGIEVA 等: "SYNTHESIS, STRUCTURAL AND SPECTRAL ANALYSIS OF SOME 8-SUBSTITUTED DERIVATIVES OF 1,3,7-TRIMETHYLXANTHINE WITH ANTIPROLIPHERATIVE ACTIVITY", 《WORLD JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES》 * |
XIAOFENG XIA 等: "Image-Based Chemical Screening Identifies Drug Efflux Inhibitors in Lung Cancer Cells", 《CANCER RESEARCH》 * |
Also Published As
Publication number | Publication date |
---|---|
CN105147693B (zh) | 2018-01-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Ling et al. | Combination of metformin and sorafenib suppresses proliferation and induces autophagy of hepatocellular carcinoma via targeting the mTOR pathway | |
Li et al. | Functional polysaccharide Lentinan suppresses human breast cancer growth via inducing autophagy and caspase-7-mediated apoptosis | |
Ruan et al. | Autophagy inhibition enhances isorhamnetin‑induced mitochondria‑dependent apoptosis in non‑small cell lung cancer cells | |
Li et al. | Inhibitory effect of berberine on human skin squamous cell carcinoma A431 cells | |
Zhou et al. | A novel synthetic curcumin derivative MHMM-41 induces ROS-mediated apoptosis and migration blocking of human lung cancer cells A549 | |
Yu et al. | Resveratrol activates PI3K/AKT to reduce myocardial cell apoptosis and mitochondrial oxidative damage caused by myocardial ischemia/reperfusion injury | |
Feng et al. | Old targets, new strategy: Apigenin-7-O-β-d-(-6 ″-p-coumaroyl)-glucopyranoside prevents endothelial ferroptosis and alleviates intestinal ischemia-reperfusion injury through HO-1 and MAO-B inhibition | |
CN107586781A (zh) | 肝癌标志物lncRNA ENST00000620463.1及其应用 | |
Byun et al. | Hesperidin structurally modified by gamma irradiation induces apoptosis in murine melanoma B16BL6 cells and inhibits both subcutaneous tumor growth and metastasis in C57BL/6 mice | |
Li et al. | Jinlong Capsule (JLC) inhibits proliferation and induces apoptosis in human gastric cancer cells in vivo and in vitro | |
Xue et al. | Synergistic effect of meta-tetra (hydroxyphenyl) chlorin-based photodynamic therapy followed by cisplatin on malignant Hep-2 cells | |
Li et al. | Detection of nano Eu2O3 in cells and study of its biological effects | |
CN105147693A (zh) | 一种小分子化合物在制备抗肺癌药物中的应用 | |
CN115590914A (zh) | 一种红大戟提取物及其在制备抗乳腺癌药物中的应用 | |
Zhang et al. | Oxymatrine pretreatment protects H9c2 cardiomyocytes from hypoxia/reoxygenation injury by modulating the PI3K/Akt pathway | |
Li et al. | The enhanced treatment efficacy of invasive brain glioma by dual-targeted artemether plus paclitaxel micelles | |
CN111870695B (zh) | miR-223-3p抑制因子在制备治疗白癜风的药物中的应用 | |
CN111560433B (zh) | 人nufip1的用途及相关产品 | |
Lu et al. | Dipsacus Asperoides-Derived Exosomes-Like Nanoparticles Inhibit the Progression of Osteosarcoma via Activating P38/JNK Signaling Pathway | |
Lele et al. | Resveratrol sensitizes A549 cells to irradiation damage via suppression of store‑operated calcium entry with Orai1 and STIM1 downregulation | |
Wang et al. | Wogonin Diminishes Radioresistance of Breast Cancer via Inhibition of the Nrf2/HIF-1 α Pathway | |
Liu et al. | A composition of ursolic acid derivatives from Ludwigia hyssopifolia induces apoptosis in throat cancer cells via the Akt/mTOR and mitochondrial signaling pathways and by modulating endoplasmic reticulum stress | |
Tian et al. | mTOR signaling pathway is inhibited downstream of the cyclophilin D-mediated mitochondrial permeability transition in honokiol-triggered regulated necrosis | |
CN105078958A (zh) | 淫羊藿素在制备抗nk/t细胞淋巴瘤药物中的用途 | |
CN114366740B (zh) | 化合物a-6在制备广谱抗癌药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |